Spotlight: Defining the undefinable: The challenges and opportunities for cell & gene therapy IP

Effective IP strategy for C&GTs presents unique challenges compared to traditional pharmaceuticals and biologics. To secure robust IP that protects the market and attracts investors, companies need to think beyond the process and tackle head-on the challenge of defining these inherently complex products.